Differential sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to Taxol for apoptosis

作者: Ran Zhang , Naren L. Banik , Swapan K. Ray

DOI: 10.1016/J.BRAINRES.2008.08.075

关键词:

摘要: Glioblastoma is the most malignant brain tumor in humans and an average survival of glioblastoma patients hardly exceeds 12 months. Taxol a plant-derived anti-cancer agent, which has been used treatments many solid tumors. Deletion or mutation phosphatase tension homolog located on chromosome ten (PTEN) occurs more than 80% glioblastomas. We examined sensitivity human LN18 (PTEN-positive) A172 (PTEN-negative) cells to for induction apoptosis. Wright staining showed morphological features apoptosis after treatment with different doses 24 h. Significant amount occurred 25 nM Taxol, while only 50 Taxol. Western blotting antibody that could specifically detect activation phosphorylation Akt (p-Akt) did not show any p-Akt but increase cells. Activation be reversed by pre-treatment phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002, indicating involvement PI3K activity this process. Apoptosis Bax:Bcl-2 mitochondrial release cytochrome c into cytosol leading mitochondria-dependent caspase cascade. cause upregulation vascular endothelial growth factor (VEGF), key mediator angiogenesis, substantial VEGF After increases maintain respectively, PTEN-negative glioblastoma. As single chemotherapy, might efficacious PTEN-positive Thus, our study differential

参考文章(50)
Mark A. Rosenthal, Michael L. Gruber, Jon Glass, Anita Nirenberg, Jonathan Finlay, Howard Hochster, Franco M. Muggia, Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme. Journal of Neuro-oncology. ,vol. 47, pp. 59- 63 ,(2000) , 10.1023/A:1006426215005
Lorenzo Bello, Carlo Giussani, Giorgio Carrabba, Mauro Pluderi, Francesco Costa, Andreas Bikfalvi, Angiogenesis and invasion in gliomas. Cancer treatment and research. ,vol. 117, pp. 263- 284 ,(2004) , 10.1007/978-1-4419-8871-3_16
E. Antonio Chiocca, Edyta Tyminski, Hiroaki Wakimoto, James P. Basilion, Kinya Terada, Tatsuya Abe, Ryo Inoue, Robert Bookstein, PTEN Decreases in Vivo Vascularization of Experimental Gliomas in Spite of Proangiogenic Stimuli Cancer Research. ,vol. 63, pp. 2300- 2305 ,(2003)
Tetsuro Sano, Huai Lin, Xiashan Chen, Lauren A Langford, Dimpy Koul, Melissa L Bondy, Kenneth R Hess, Jeffrey N Myers, Yong-Kil Hong, WK Alfred Yung, Peter A Steck, None, Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Research. ,vol. 59, pp. 1820- 1824 ,(1999)
J. M. Adams, The Bcl-2 Protein Family: Arbiters of Cell Survival Science. ,vol. 281, pp. 1322- 1326 ,(1998) , 10.1126/SCIENCE.281.5381.1322
Mary Ann Jordan, Leslie Wilson, Microtubules as a target for anticancer drugs. Nature Reviews Cancer. ,vol. 4, pp. 253- 265 ,(2004) , 10.1038/NRC1317
Candelaria Gomez-Manzano, Juan Fueyo, Hong Jiang, Tricia L. Glass, Ho-Young Lee, Min Hu, Juinn-Lin Liu, Sushma L. Jasti, Ta-Jen Liu, Charles A. Conrad, W. K. Alfred Yung, Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis Annals of Neurology. ,vol. 53, pp. 109- 117 ,(2003) , 10.1002/ANA.10396
David A. Reardon, Annick Desjardins, Jeremy N. Rich, James J. Vredenburgh, The emerging role of anti-angiogenic therapy for malignant glioma. Current Treatment Options in Oncology. ,vol. 9, pp. 1- 22 ,(2008) , 10.1007/S11864-008-0052-6
William C Rose, Taxol: a review of its preclinical in vivo antitumor activity. Anti-Cancer Drugs. ,vol. 3, pp. 311- 321 ,(1992) , 10.1097/00001813-199208000-00001